

A Bamias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11048435/publications.pdf>

Version: 2024-02-01

47
papers

1,508
citations

331259

21
h-index

315357

38
g-index

47
all docs

47
docs citations

47
times ranked

2159
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of COVID-19 with impaired endothelial glycocalyx, coronary flow and longitudinal strain four months after infection. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, .	0.5	0
2	Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial efficiency four months after infection. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, .	0.5	0
3	Effects of hormone replacement therapy on arterial stiffness, endothelial function and myocardial deformation in women with Turner syndrome. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, .	0.5	0
4	SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. <i>ESMO Open</i> , 2021, 6, 100152.	2.0	6
5	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. <i>ESMO Open</i> , 2021, 6, 100241.	2.0	13
6	Effects of hormone replacement therapy on endothelial function, arterial stiffness and myocardial deformation in women with Turner syndrome. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
7	First-degree relatives of type-2 diabetic patients and dysglycaemic patients have impaired endothelial function due to decreased bioavailability of nitric oxide. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
8	Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108331.	1.1	53
9	Axitinib as a third or further line of treatment in renal cancer: a single institution experience. <i>BMC Urology</i> , 2020, 20, 60.	0.6	3
10	Differential effect of anthracycline and trastuzumab cancer therapeutic related vascular toxicity in patients with breast cancer. <i>European Heart Journal</i> , 2020, 41, .	1.0	1
11	Inhibition of the Hedgehog pathway in lung cancer. <i>Lung Cancer</i> , 2019, 133, 56-61.	0.9	13
12	Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. <i>Supportive Care in Cancer</i> , 2019, 27, 4535-4542.	1.0	10
13	P1573 Chemotherapy-induced vasotoxicity in patients undergoing therapy for breast cancer. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
14	EAU "ESMO consensus statements on the management of advanced and variant bladder cancer" an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
15	Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>Annals of Oncology</i> , 2018, 29, 361-369.	0.6	57
16	P1577 Cancer therapeutic related vaso- and cardio-toxicity in patients receiving chemotherapy for breast cancer. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
17	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848.	0.6	43
18	Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). <i>Annals of Oncology</i> , 2016, 27, 1006-1013.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Patterns of practice in oncology: is progress reaching our practice?. <i>European Journal of Cancer Care</i> , 2015, 24, 768-770.	0.7	0
20	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 36-49.	2.0	18
21	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014, 110, 1917-1922.	2.9	64
22	Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). <i>Annals of Oncology</i> , 2013, 24, 1011-1017.	0.6	87
23	VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. <i>British Journal of Cancer</i> , 2012, 107, 1869-1875.	2.9	126
24	Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor. <i>European Journal of Cancer</i> , 2012, 48, 1476-1483.	1.3	43
25	Angiogenesis: A promising therapeutic target for ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 314-326.	2.0	37
26	The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. <i>European Journal of Cancer</i> , 2011, 47, 1660-1668.	1.3	31
27	Diagnosis and Management of Hypertension in Advanced Renal Cell Carcinoma: Prospective Evaluation of an Algorithm in Patients Treated with Sunitinib. <i>Journal of Chemotherapy</i> , 2009, 21, 347-350.	0.7	22
28	Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: Proposal for a new prognostic model. <i>Gynecologic Oncology</i> , 2008, 108, 130-135.	0.6	12
29	A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study. <i>European Journal of Cancer</i> , 2008, 44, 1693-1700.	1.3	21
30	Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study. <i>Anticancer Research</i> , 2008, 28, 2479-86.	0.5	4
31	The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 372-376.	0.6	20
32	Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. <i>Gynecologic Oncology</i> , 2007, 106, 75-81.	0.6	74
33	Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β -catenin levels and outcome in patients with epithelial ovarian cancer. <i>Annals of Oncology</i> , 2006, 17, 1797-1802.	0.6	10
34	Systemic chemotherapy in inoperable or metastatic bladder cancer. <i>Annals of Oncology</i> , 2006, 17, 553-561.	0.6	46
35	Cisplatin versus carboplatin-based chemotherapy in inoperable or recurrent urothelial carcinoma: A retrospective analysis. <i>Journal of Clinical Oncology</i> , 2006, 24, 14558-14558.	0.8	0
36	The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. <i>Gynecologic Oncology</i> , 2005, 99, 376-382.	0.6	43

#	ARTICLE	IF	CITATIONS
37	The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. <i>Annals of Oncology</i> , 2005, 16, 307-313.	0.6	64
38	Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. <i>Annals of Oncology</i> , 2005, 16, 869-877.	0.6	62
39	Late relapse of epithelial ovarian cancer: a single institution experience. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2005, 26, 439-42.	0.3	4
40	Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2150-2154.	0.8	87
41	Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 220-228.	0.8	190
42	Neoadjuvant Chemotherapy with Docetaxel and Cisplatin in Patients with High-Risk Resectable Bladder Carcinoma: Long Term Results. <i>European Urology</i> , 2004, 46, 344-351.	0.9	6
43	ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED BLADDER CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP. <i>Journal of Urology</i> , 2004, 171, 1467-1470.	0.2	19
44	A Phase II Study with CPT-11 Plus Leucovorin and Bolus IV 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma. <i>Cancer Investigation</i> , 2003, 21, 855-862.	0.6	7
45	Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 1999, 10, 1385-1388.	0.6	64
46	Intravesical administration of indium-111-labelled hmfg2 monoclonal antibody in superficial bladder carcinomas. <i>International Journal of Cancer</i> , 1993, 54, 899-903.	2.3	20
47	Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma. <i>Cancer Research</i> , 1991, 51, 724-8.	0.4	25